{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:31:33Z","timestamp":1787959893925,"version":"build-2784847793"},"update-to":[{"DOI":"10.1002\/14651858.cd003333.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T00:00:00Z","timestamp":1473897600000}}],"reference-count":40,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003333.pub3","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T13:50:58Z","timestamp":1473947458000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm"],"prefix":"10.1002","author":[{"given":"Eduard","family":"Shantsila","sequence":"first","affiliation":[{"name":"City Hospital, Sandwell and West Birmingham Hospitals NHS Trust; University of Birmingham, Institute of Cardiovascular Sciences; Birmingham UK B18 7QH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory YH","family":"Lip","sequence":"additional","affiliation":[{"name":"University of Liverpool; Institute of Ageing and Chronic Disease; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"key":"10.1002\/14651858.CD003333.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejheart.2006.02.012","article-title":"Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study","volume":"8","author":"Cokkinos","year":"2006","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","article-title":"Warfarin and aspirin in patients with heart failure and sinus rhythm","volume":"366","author":"Homma","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2004.03.010","article-title":"The Warfarin\/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure","volume":"148","author":"Cleland","year":"2004","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/CIRCULATIONAHA.108.801753","article-title":"Randomized trial of warfarin, aspirin and clopidogrel in patients with chronic heart failure. The warfarin and antiplatelet therapy in chronic heart failure (WATCH) trial","volume":"119","author":"Massie","year":"2009","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0735-1097(97)00502-0","article-title":"Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial","volume":"31","author":"Al-Khadra","year":"1998","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0006|cit6","unstructured":"Liu PY Li YH Chen JH Tsai LM Liao JK A double-blind randomized placebo pilot study comparing aggrenox versus placebo in heart failure patients (ASAP-HF trial) European Journal of Heart Failure 2013 S74"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0007|cit7","first-page":"159","article-title":"A randomized controlled trial of aspirin compared to clopidogrel in patients with heart failure","volume":"35","author":"Parsons","year":"2014","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0008|cit8","first-page":"267","article-title":"The clopidogrel or aspirin in chronic heart failure (CACHE) study","volume":"16","author":"Parsons","year":"2014","journal-title":"European Journal of Heart Failure"},{"issue":"5","key":"10.1002\/14651858.CD003333.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S1388-9842(02)00028-4","article-title":"Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction severe heart failure and left ventricular systolic dysfunction (EPICAL study)","volume":"4","author":"Echemann","year":"2002","journal-title":"European Journal of Heart Failure"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003333.pub3-BIB0010|cit10","first-page":"218A","article-title":"The effect of warfarin on prevalence of stroke in patients with severe heart failure","volume":"21","author":"Falk","year":"1993","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJM199701233360403","article-title":"Ventricular dysfunction and the risk of stroke after myocardial infarction","volume":"336","author":"Loh","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0002-9149(97)00013-1","article-title":"Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure","volume":"79","author":"Dries","year":"1997","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0735-1097(97)00019-3","article-title":"Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials","volume":"29","author":"Dries","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD003333.pub3-BIB0014|cit14","first-page":"VI194","article-title":"Incidence of thromboembolic events in congestive heart failure","volume":"87","author":"Dunkman","year":"1993","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0015|cit15","unstructured":"NCT01877915 A sStudy to assess the effectiveness and safety of rivaroxaban in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and coronary artery disease following an episode of decompensated heart failure (COMMANDER HF) clinicaltrials.gov\/ct2\/show\/NCT01877915"},{"issue":"4","key":"10.1002\/14651858.CD003333.pub3-BIB0016|cit16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001925.pub2","article-title":"Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks","author":"Aguilar","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10654-010-9520-y","article-title":"Heart failure and the risk of stroke: the Rotterdam Study","volume":"25","author":"Alberts","year":"2010","journal-title":"European Journal of Epidemiology"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy - I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists' Collaboration","year":"1994","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bmj.308.6922.159","article-title":"Collaborative overview of randomised trials of antiplatelet therapy - II:Maintenance of vascular graft or arterial patency by antiplatelet therapy","volume":"308","author":"Antiplatelet Trialists' Collaboration","year":"1994","journal-title":"BMJ"},{"issue":"9678","key":"10.1002\/14651858.CD003333.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists' Collaboration","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0023|cit23","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/TH11-03-0168","article-title":"Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show underutilisation of preventive therapies","volume":"106","author":"Khoury","year":"2011","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0735-1097(86)80489-2","article-title":"Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary preventionwith persantine and aspirin","volume":"7","author":"Klimt","year":"1986","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0026|cit26","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1160\/TH12-08-0578","article-title":"Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis","volume":"108","author":"Lip","year":"2012","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD003333.pub3-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003336.pub3","article-title":"Anticoagulation versus placebo for heart failure in sinusrhythm","author":"Lip","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effects of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"Packer","year":"1991","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.amjmed.2010.10.014","article-title":"Venous thromboembolism in heart failure: preventable deaths during and after hospitalization","volume":"124","author":"Piazza","year":"2011","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000352058","article-title":"Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial","volume":"36","author":"Pullicino","year":"2013","journal-title":"Cerebrovascular Diseases"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pcad.2015.09.005","article-title":"Preventing thrombosis to improve outcomes in heart failure patients","volume":"58","author":"Shantsila","year":"2016","journal-title":"Progress in Cardiovascular Diseases"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators","year":"1992","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"658S","DOI":"10.1378\/chest.114.5_Supplement.658S","article-title":"Antithrombotic therapy in patients with saphenous vein and internal mammaryartery bypass grafts","volume":"114(5 Suppl)","author":"Stein","year":"1998","journal-title":"Chest"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0036|cit36","first-page":"573","article-title":"Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004)","volume":"6","author":"Stewart","year":"2010","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/01.STR.19.4.436","article-title":"Antiplatelet agents in the secondary prevention of stroke: meta-analysis of the randomized control trials","volume":"19","author":"Sze","year":"1988","journal-title":"Stroke"},{"issue":"2","key":"10.1002\/14651858.CD003333.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1212\/WNL.54.2.288","article-title":"Stroke in patients with heart failure and reduced left ventricular ejection fraction","volume":"54","author":"Pullicino","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003333.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.cardfail.2007.01.009","article-title":"The incidence of ischemic stroke in chronic heart failure: a meta-analysis","volume":"6","author":"Witt","year":"2007","journal-title":"Journal of Cardiac Failure"},{"issue":"4","key":"10.1002\/14651858.CD003333.pub3-BIB0040|cit40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003333","article-title":"Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm","author":"Lip","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003333.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003333.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:19:12Z","timestamp":1628543952000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003333.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Heart Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003333.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,15]]}}}